ProQR Therapeutics (PRQR) Income towards Parent Company (2021 - 2025)
Historic Income towards Parent Company for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$12.9 million.
- ProQR Therapeutics' Income towards Parent Company fell 3836.62% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year decrease of 8678.42%. This contributed to the annual value of -$30.0 million for FY2024, which is 120.94% up from last year.
- Latest data reveals that ProQR Therapeutics reported Income towards Parent Company of -$12.9 million as of Q3 2025, which was down 3836.62% from -$14.6 million recorded in Q2 2025.
- ProQR Therapeutics' Income towards Parent Company's 5-year high stood at -$2.9 million during Q2 2024, with a 5-year trough of -$23.5 million in Q3 2022.
- Over the past 5 years, ProQR Therapeutics' median Income towards Parent Company value was -$12.9 million (recorded in 2025), while the average stood at -$12.6 million.
- In the last 5 years, ProQR Therapeutics' Income towards Parent Company surged by 7201.08% in 2023 and then crashed by 40218.09% in 2025.
- ProQR Therapeutics' Income towards Parent Company (Quarter) stood at -$20.8 million in 2021, then skyrocketed by 34.92% to -$13.6 million in 2022, then surged by 60.85% to -$5.3 million in 2023, then plummeted by 85.19% to -$9.8 million in 2024, then crashed by 31.09% to -$12.9 million in 2025.
- Its Income towards Parent Company stands at -$12.9 million for Q3 2025, versus -$14.6 million for Q2 2025 and -$11.0 million for Q1 2025.